About: Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$0.09 (-1.16%)
PTXASXPrescient Therapeutics Ltd
Loading watchlist status…
Prescient Therapeutics Ltd share price
PTX price activity
Last Price
Change (24hr)
AUD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
PTX price performance
-1.16%
5D
16.44%
1M
1.19%
YTD
84.78%
1Y
PTX price fundamentals
N/A
Shares Issued
N/A
Earnings Per Share (EPS)
N/A
Dividends Per Share (DPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
AU-ASX rank
N/ASector Rank
N/APTX Market Signals